Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
NCT04636554 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-12-21
Summary
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
Conditions
- Covid19
- Bacteremia
- Septicemia
- Acinetobacter Baumannii Infection
- Pseudomonas Aeruginosa Infection
- Staph Aureus Infection
Interventions
- OTHER
-
Phage Therapy
Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
Sponsors & Collaborators
-
Adaptive Phage Therapeutics, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
NCT00814151 ·Status: COMPLETED
-
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
NCT05177107 ·Status: TERMINATED ·Phase: PHASE2
-
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
NCT05020145 ·Status: COMPLETED
-
Phage Therapy for the Treatment of Urinary Tract Infection
NCT05537519 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
NCT01018641 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
NCT04597242 ·Status: NO_LONGER_AVAILABLE
-
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
NCT06456424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Mayo Clinic Phage Program Biobank
NCT05314426 ·Status: ENROLLING_BY_INVITATION
-
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
NCT03162250 ·Status: COMPLETED ·Phase: PHASE1
-
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
NCT02357966 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
NCT04832932 ·Status: ACTIVE_NOT_RECRUITING
-
Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force
NCT06368388 ·Status: RECRUITING
-
Bacteriophage Therapy of Difficult-to-treat Infections
NCT05498363 ·Status: COMPLETED
-
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
NCT05184764 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)
NCT00358462 ·Status: COMPLETED ·Phase: PHASE3
-
PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.
NCT06185920 ·Status: RECRUITING
-
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
NCT03395769 ·Status: NO_LONGER_AVAILABLE
-
Trial of MRSA Polymerase Chain Reaction for Pneumonia
NCT02660554 ·Status: COMPLETED ·Phase: NA
-
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
NCT00631566 ·Status: COMPLETED ·Phase: NA
-
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00084266 ·Status: COMPLETED ·Phase: PHASE4
-
Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia
NCT06695832 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
NCT04320615 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
NCT04353518 ·Status: UNKNOWN ·Phase: PHASE3
-
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
NCT03489629 ·Status: COMPLETED ·Phase: PHASE2
-
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
NCT05979545 ·Status: RECRUITING ·Phase: PHASE4